Graphical Research.jpg
Antiviral Drugs Market Size & Share | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
12 avr. 2021 06h00 HE | Graphical Research
Pune, India, April 12, 2021 (GLOBE NEWSWIRE) -- The global antiviral drugs market size is anticipated to witness accelerated growth during the forecast period due to the growing focus toward...
Hausfeld logo
Celgene Rescinds Agreement to Compensate Cancer Patients Days Before Christmas
08 janv. 2020 13h36 HE | Hausfeld
WASHINGTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- On December 23, 2019, Celgene backed out of a settlement in which it had agreed to pay $55 million to end payors (consumers, insurers, union health and...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports First Quarter 2016 Financial Results
09 mai 2016 16h10 HE | Agile Therapeutics, Inc.
Cash Expected to Fund Operations through the End of 2017Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 ...
Sucampo Announces Resolution of Par Pharmaceutical's ANDA for RESCULA(R)
11 févr. 2015 16h02 HE | Sucampo Pharmaceuticals Inc
BETHESDA, Md., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo and R-Tech Ueno, Ltd. (RTU),...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
09 sept. 2014 07h00 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the...
InnoPharma Logo
InnoPharma Inc. Announces Commercial Launch of Acamprosate Delayed-Release Tablets in the United States
15 août 2013 08h00 HE | InnoPharma, Inc
PISCATAWAY, NJ, Aug. 15, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc. today announced the launch of acamprosate calcium, 333 mg delayed-release tablets  (generic equivalent of Campral®). ...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Announces Fiscal Year 2013 Third Quarter Investor Conference Call on Tuesday, February 19, 2013
13 févr. 2013 08h00 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Naltrexone
06 févr. 2013 08h00 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that on January 31, 2012, the U.S. Food and Drug Administration approved the...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Announces First Shipments From Expanded 15,000 Square Foot Facility
28 janv. 2013 08h00 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that Elite is now using and shipping packaged product from its...
PBMI Survey Finds Retail Copays Are Increasing Across All Drug Types
19 déc. 2012 11h12 HE | Pharmacy Benefit Management Institute
PLANO, TX--(Marketwire - Dec 19, 2012) -  Retail copays are on the rise again across all drug types, including generics, brands and specialty drugs. This is just one of the reported...